Live
- BJP MP candidate Bharat Prasad visited the student who tried to commit suicide
- PM’s popularity in the fast lane: Autos with 'Har Dil Mein Modi' slogan spotted across Delhi
- Delhi-based political parties are like East India Company: Sukhbir Badal
- Golf: Diksha moves into Top-20 at South African Women’s Open
- KCR lashes out against BJP and Congress for destroying Telangana
- Dairy Science students visited the Milk cooling plant
- Moody feels Pant ahead in keepers’ race for T20 WC squad; Srikkanth picks Rahul over Samson as reserve keeper
- Thanking voters for extending 'unparalleled support' to NDA, PM Modi says second phase 'too good'
- Natural Relief for Menstrual Cramps: Beetroot Juice Recipe
- Asha Worker died in a road accident
Granules generic pain reliever gets FDA nod
Granules India Ltd on Thursday announced that the US Food and Drug Administration approved its Abbreviated New Drug Application (ANDA) for Acetaminophen 650 mg Tablets, Extended Release, a generic version of Tylenol 650mg tablets, Extended Release
Hyderabad: Granules India Ltd on Thursday announced that the US Food and Drug Administration approved its Abbreviated New Drug Application (ANDA) for Acetaminophen 650 mg Tablets, Extended Release, a generic version of Tylenol 650mg tablets, Extended Release.
Acetaminophen 650 mg extended release tablets are used primarily for temporary pain management including arthritis relief, said the city-based drug maker.
"The addition of Acetaminophen 650mg, extended release tablets to our OTC ( Over the Counter) portfolio leverages several components of our value proposition," Krishna Prasad Chigurupati, CMD of Granules India said.
Granules India is the only supplier that is equipped with backward integration up to the Active Pharmaceutical Ingredient of this product, he added.
"With a capacity of over 24,000 tonnes per annum Acetaminophen API and finished dosage capacity of more than 18 billion units/year, we are confident that we will ensure supply security to our customers which will support us to capture our target market share," Chigurupati said.
